Getting the Right Evidence After Drug Approval

Rick A. Vreman; Rick A. Vreman; Hubert G. M. Leufkens; Aaron S. Kesselheim

doi:10.3389/fphar.2020.569535

Frontiers in Pharmacology (Sep 2020)

Getting the Right Evidence After Drug Approval

Rick A. Vreman,
Rick A. Vreman,
Hubert G. M. Leufkens,
Aaron S. Kesselheim

Affiliations

Rick A. Vreman: Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands
Rick A. Vreman: National Health Care Institute (ZIN), Diemen, Netherlands
Hubert G. M. Leufkens: Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands
Aaron S. Kesselheim: Program on Regulation, Therapeutics and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, United States

DOI: https://doi.org/10.3389/fphar.2020.569535
Journal volume & issue: Vol. 11

Abstract

Read online

To generate comparative evidence in a timely fashion for drugs without restricting or delaying access, value-based pricing and reimbursement could be conditioned on a prospective, post-approval evidence generation plan.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords